Evidence map›Paper›PMID 42437533›Full record

ArticleBriefings in bioinformatics2026

AbTune: layer-wise selective fine-tuning of protein language models for antibodies.

Xiaotong Xu, Alexandre M J J Bonvin

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiaotong XuBijvoet Centre for Biomolecular Research, Faculty of Science, Chemistry, Utrecht University, Heidelberglaan 8, 3584 CS Utrecht, Netherlands.
Alexandre M J J BonvinBijvoet Centre for Biomolecular Research, Faculty of Science, Chemistry, Utrecht University, Heidelberglaan 8, 3584 CS Utrecht, Netherlands.

Funding

BioExcel 101093290China Scholarship Council 202208310024European High Performance Computing JointUndertakingGANANA 101196247
6 · The paper itself

Abstract

Antibodies play central roles in immune defense and are widely used as therapeutic agents. However, the high structural and sequence diversity of antigen-binding loops, combined with limited experimental data and weak co-evolutionary signals, makes it difficult to develop generalizable predictive models. In this work, we investigate test-time fine-tuning strategies to improve protein language model (pLM) performance in low-data settings, with a focus on antibody-related tasks. Systematic evaluations across tasks show that carefully constrained fine-tuning greatly enhances performance while preserving generalization. In particular, depth-selective fine-tuning consistently outperforms full-depth fine-tuning, with optimal performance achieved when tuning 50%-75% of model layers for medium- to small-sized pLMs. We introduce AbTune, a test-time fine-tuning framework that leverages this depth-controlled adaptation strategy. Across antibody structure prediction, mutation effect prediction, and binding affinity prediction, AbTune outperforms both standard pLM baselines and task-specific predictors, achieving the best performance among the evaluated baselines on two of the three tasks. To gain insight into the adaptation process and identify optimal AbTune protocols, we analyzed representation shifts, examined how sequence properties influence fine-tuning dynamics, and evaluated metrics that capture potential overfitting. Our results show that fine-tuning depth, duration, and perplexity jointly influence performance and must be carefully controlled to achieve optimal results.

Indexed as

AntibodiesAlgorithmsHumansModels, MolecularAntibodiesantibodiesbinding affinity predictionfine-tuningprotein language model

Identifiers

PMID42437533
PMCPMC13356902

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.